¼¼°èÀÇ ¸¶ÀÌÅ©·Î RNA(miRNA) ½ÃÀå
microRNA (miRNA)
»óǰÄÚµå : 1760954
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 379 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,101,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,303,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¸¶ÀÌÅ©·Î RNA(miRNA) ¼¼°è ½ÃÀåÀº 2030³â±îÁö 8¾ï 2,910¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 3¾ï 9,620¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¸¶ÀÌÅ©·Î RNA(miRNA) ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 13.1%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 8¾ï 2,910¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®Çϰí ÀÖ´Â ºÎ¹® Áß ÇϳªÀÎ Á¦Ç°Àº CAGR 11.4%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 4¾ï 1,180¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼­ºñ½º ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 14.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 5,430¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 16.3%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¸¶ÀÌÅ©·Î RNA(miRNA) ½ÃÀåÀº 2024³â¿¡ 1¾ï 5,430¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 8,820¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 16.3%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 11.1%¿Í 11.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 11.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¸¶ÀÌÅ©·Î RNA(miRNA) ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¸¶ÀÌÅ©·Î RNA(miRNA)´Â ÀúºÐÀÚ ºñ¾Ïȣȭ RNA ºÐÀÚÀÇ ÀÏÁ¾À¸·Î, Àü»ç ÈÄ ¼öÁØ¿¡¼­ À¯ÀüÀÚ ¹ßÇö Á¶Àý¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀϹÝÀûÀ¸·Î ¾à 22 ´ºÅ¬·¹¿ÀƼµå ±æÀÌÀÇ miRNA´Â Ç¥Àû ¸Þ½ÅÀú RNA(mRNA) Àü»çüÀÇ »óº¸Àû ¼­¿­¿¡ °áÇÕÇÏ¿© ÀϹÝÀûÀ¸·Î ¹ø¿ª ¾ïÁ¦ ¶Ç´Â Ç¥Àû ºÐÇØ¸¦ ÅëÇØ À¯ÀüÀÚ Ä§¹¬À» ÃÊ·¡Çϸç, miRNAÀÇ ¹ß°ßÀº À¯ÀüÀÚ°¡ ¼¼Æ÷ ³»¿¡¼­ ¾î¶»°Ô Á¶ÀýµÇ´ÂÁö¿¡ ´ëÇÑ ÀÌÇØ¸¦ Å©°Ô ÁøÀü½ÃÄ×½À´Ï´Ù. ¹ß»ý, ºÐÈ­, ´ë»ç¸¦ Æ÷ÇÔÇÑ ±¤¹üÀ§ÇÑ »ý¹°ÇÐÀû °úÁ¤¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ´Ù¾çÇÑ ¼¼Æ÷ ³» °æ·Î¿¡ °ü¿©Çϱ⠶§¹®¿¡ miRNA´Â ¸¹Àº Áúº´, ƯÈ÷ ¾Ï, ½ÉÇ÷°üÁúȯ, ½Å°æ ÅðÇ༺ ÁúȯÀÇ º´Å»ý¸®¿¡µµ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù.

miRNA¿¡ ´ëÇÑ ¿¬±¸°¡ ±ÞÁõÇϰí ÀÖÀ¸¸ç, Áúº´ÀÇ Áø´Ü ¹× ¿¹ÈÄ ¹ÙÀÌ¿À¸¶Ä¿·Î¼­, ±×¸®°í Ä¡·áÀû °³ÀÔÀÇ Ç¥ÀûÀ¸·Î¼­ÀÇ ÀáÀç·ÂÀÌ ¹àÇôÁö°í ÀÖÀ¸¸ç, miRNA¸¦ ¿¬±¸Çϱâ À§ÇÑ µµ±¸¿Í ±â¼úµµ ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º µµ±¸¿¡ À̸£±â±îÁö ´Ù¾çÇÕ´Ï´Ù. ÀÓ»óÀû Ãø¸é¿¡¼­, miRNA ±â¹Ý Áø´ÜÀº ƯÁ¤ Áúȯ°ú °ü·ÃµÈ ƯÁ¤ miRNA¸¦ ½Äº°ÇÏ¿© Á¶±â ¹ß°ß ¹× º¸´Ù ¸ÂÃãÈ­µÈ Ä¡·á °èȹÀ¸·Î À̾îÁú ¼ö ÀÖ´Â °¡´É¼ºÀ» Á¦½ÃÇÕ´Ï´Ù. ¶ÇÇÑ, ƯÁ¤ miRNAÀÇ ±â´ÉÀ» Á¶ÀýÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ´Â miRNA Ä¡·áÁ¦ÀÇ °³¹ßµµ ÁøÇàµÇ°í ÀÖÀ¸¸ç, ÀϺΠÈĺ¸¹°ÁúÀº ÀüÀÓ»ó ¹× ÀÓ»ó½ÃÇè ´Ü°è¿¡ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á Àü·«¿¡´Â ¼¼Æ÷ÀÇ Á¤»ó ±â´ÉÀ» ȸº¹Çϵµ·Ï ¼³°èµÈ ÇÕ¼º miRNAÀÎ miRNA ¸ð¹æÃ¼¿Í Áúº´ ÁøÇà¿¡ °ü¿©ÇÏ´Â miRNAÀÇ ±â´ÉÀ» ¾ïÁ¦ÇÏ´Â miRNA ¾ïÁ¦Á¦°¡ Æ÷ÇԵ˴ϴÙ.

miRNA ½ÃÀåÀÇ ¼ºÀåÀº miRNA ÇÁ·ÎÆÄÀϸµ ±â¼úÀÇ ¹ßÀü, miRNA ¿¬±¸ ¹× Ä¡·áÁ¦ °³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, Á¤¹ÐÀÇ·á¿¡¼­ miRNAÀÇ ÀáÀç·Â¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ±â¼úÀÇ ¹ßÀüÀ¸·Î miRNAÀÇ °ËÃâ ¹× Á¤·®È­°¡ º¸´Ù È¿À²ÀûÀÌ°í ºñ¿ë È¿À²ÀûÀÎ ¹æ½ÄÀ¸·Î ÀÌ·ç¾îÁö¸é¼­ ¿¬±¸ ¹× ÀÓ»ó ºÐ¾ß ¸ðµÎ¿¡¼­ miRNAÀÇ Àû¿ë °¡´É¼ºÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. Á¦¾à ¹× »ý¸í°øÇÐ ºÐ¾ß´Â Áúº´ °æ·ÎÀÇ ¿©·¯ Ãø¸éÀ» Ç¥ÀûÀ¸·Î »ïÀ» ¼ö ÀÖ´Â miRNAÀÇ ´É·Â¿¡ ¸Å·áµÇ¾î miRNA ±â¹Ý Ä¡·áÁ¦ °³¹ß¿¡ Á¡Á¡ ´õ ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇコÄÉ¾î »ê¾÷ÀÌ º¸´Ù °³ÀÎÈ­µÈ Ä¡·á¹ýÀ» Ãß±¸ÇÔ¿¡ µû¶ó miRNA Áø´Ü ¹× Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ƯÁ¤ miRNA¸¦ ƯÁ¤ Áúº´°ú ¿¬°ü½ÃŰ´Â ¿¬±¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¹ÙÀÌ¿À¸¶Ä¿ ¹× Ä¡·á Ç¥ÀûÀ¸·Î¼­ÀÇ miRNAÀÇ ÀÓ»óÀû °¡Ä¡¸¦ ´õ¿í µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(Á¦Ç°, ¼­ºñ½º), ¿ëµµ(¾Ï, °¨¿°Áõ, ¸é¿ªÁúȯ, ½ÉÇ÷°üÁúȯ, ½Å°æÁúȯ, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(Çмú¡¤Á¤ºÎ ¿¬±¸±â°ü, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¡¤Á¦¾à ±â¾÷, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê(ÃÑ 64°³»ç)

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°èÀÇ Àü¹®°¡¿¡¼­ Å¥·¹ÀÌÆ® µÈ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global microRNA (miRNA) Market to Reach US$829.1 Million by 2030

The global market for microRNA (miRNA) estimated at US$396.2 Million in the year 2024, is expected to reach US$829.1 Million by 2030, growing at a CAGR of 13.1% over the analysis period 2024-2030. Products, one of the segments analyzed in the report, is expected to record a 11.4% CAGR and reach US$411.8 Million by the end of the analysis period. Growth in the Services segment is estimated at 14.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$154.3 Million While China is Forecast to Grow at 16.3% CAGR

The microRNA (miRNA) market in the U.S. is estimated at US$154.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$88.2 Million by the year 2030 trailing a CAGR of 16.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.1% and 11.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.8% CAGR.

Global microRNA (miRNA) Market - Key Trends and Drivers Summarized

MicroRNAs (miRNAs) are a class of small, non-coding RNA molecules that play a crucial role in regulating gene expression at the post-transcriptional level. Typically about 22 nucleotides long, miRNAs bind to complementary sequences on target messenger RNA (mRNA) transcripts, usually resulting in gene silencing via translational repression or target degradation. The discovery of miRNAs has significantly advanced our understanding of how genes are regulated in cells and has implications for a wide range of biological processes including development, differentiation, and metabolism. Given their involvement in various cellular pathways, miRNAs are also considered vital in the pathology of numerous diseases, notably cancer, cardiovascular diseases, and neurodegenerative disorders.

Research into miRNAs has burgeoned, revealing their potential as biomarkers for disease diagnosis and prognosis, as well as targets for therapeutic intervention. Tools and technologies to study miRNAs have also evolved, ranging from advanced sequencing techniques to bioinformatics tools designed to predict miRNA targets and functions. In the clinical context, miRNA-based diagnostics have shown promise in identifying specific miRNAs associated with particular disease states, which can lead to early detection and more personalized treatment plans. Moreover, miRNA therapeutics, which aim to modulate the function of specific miRNAs, are in development, with several candidates in preclinical and clinical trials. These therapeutic strategies include miRNA mimics, which are synthetic miRNAs designed to restore normal function to cells, and miRNA inhibitors, which block the function of miRNAs involved in disease progression.

The growth in the miRNA market is driven by several factors, including advances in miRNA profiling technologies, increased investment in miRNA research and therapeutic development, and a growing awareness of the potential of miRNAs in precision medicine. Technological advancements have led to more efficient and cost-effective methods for detecting and quantifying miRNAs, enhancing their applicability in both research and clinical settings. The pharmaceutical and biotechnological sectors are increasingly focusing on developing miRNA-based therapeutics, attracted by their ability to target multiple aspects of disease pathways. Moreover, as the healthcare industry moves toward more personalized treatment options, the demand for miRNA diagnostics and therapeutics is expected to rise, reflecting their potential to tailor treatments to individual genetic profiles and disease conditions. This trend is bolstered by a growing body of research that links specific miRNAs to particular diseases, further underpinning the clinical value of miRNAs as both biomarkers and therapeutic targets.

SCOPE OF STUDY:

The report analyzes the microRNA (miRNA) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Products, Services); Application (Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases, Other Applications); End-Use (Academic & Government Research Institutes, Biotech & Pharma Companies, Other End-Uses)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 64 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â